Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma.
Yeong-Chin JouGuan-Ling LinHon-Yi LinWan-Hong HuangYu-Ming ChuangRu-Inn LinPie-Che ChenShu-Fen WuCheng-Huang ShenMichael Wing-Yan ChanPublished in: Cancer cell international (2021)
In conclusion, our results suggested that CPH may be an epigenetic modifier, modulating the expression of the potential tumor suppressor IRF6, in inhibiting tumor growth in UC.